Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

OBJECTIVE: To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analysis (NCT01695239). METHODS: Patients were stratifi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Coates, Laura C, Kishimoto, Mitsumasa, Gottlieb, Alice, Shuler, Catherine L, Lin, Chen-Yen, Lee, Chin Hyok, Mease, Philip J
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Psoriatic Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5743900/
https://ncbi.nlm.nih.gov/pubmed/29299340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2017-000567
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados